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ABSTRACT
Introduction: Luteinizing hormone-releasing
hormone (LHRH) analogues are widely used
for the treatment of advanced
hormone-dependent prostate cancer. However,
there are currently no clinical guidelines for
switching between LHRH analogues. It has been
reported that there may be clinical benefits for
patients switching between different
formulations of LHRH agonists, as well as from
an LHRH agonist to LHRH antagonist, but there
are no published data on switching from an
LHRH antagonist to an LHRH agonist. In this
paper, we summarize the clinical notes of 10
patients with hormone-sensitive advanced
prostate cancer who switched from an LHRH
antagonist to an LHRH agonist.
Methods: Patients with T3N0M0–T4N1M1
prostate cancer experiencing injection site
reactions, such as pain and swelling, with
monthly degarelix (Firmagon) subcutaneous
injections were switched to the 3-monthly
leuprorelin acetate implant (Leuprorelin
Sandoz) subcutaneous injections.
Results: Mean patient age was 75 years (SD 8.3;
range 59–85) and Gleason scores ranged from 7
to 9. The mean [±standard deviation (SD)]
duration of degarelix treatment was
5 ± 3.7 months (range 2–13). After switching,
prostate serum antigen levels were comparable
or reduced from those measured prior to
switching, showing that efficacy was not
compromised. Throughout the course of
treatment, no patients reported injection site
reactions. Patients reported increased
satisfaction with the leuprorelin acetate
implant versus degarelix, mainly because of a
lack of injection site reactions and reduced
frequency of injection.
Conclusion: This is the first report of the
clinical experience and potential cost
implications of switching from an LHRH
antagonist to an LHRH agonist. These data are
consistent with other experiences of switching
between LHRH analogues in terms of efficacy,
safety, and potential cost savings, and provide
preliminary evidence that the switch from an
LHRH antagonist to an agonist is safe and
equally efficacious.
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Androgen deprivation therapy (ADT) is still the
mainstay of treatment for advanced
hormone-dependent prostate cancer, with the
main form being luteinizing hormone-releasing
hormone (LHRH) agonists, such as goserelin
acetate and leuprorelin acetate [1]. If permanent
castration is required, orchiectomy is the most
cost-effective and effective treatment option,
but is very seldom used in clinical practice in
Western countries.
Luteinizing hormone-releasing hormone
(LHRH) agonists bind to the LHRH receptor
and stimulate luteinizing hormone (LH) and
follicle-stimulating hormone (FSH) secretion.
Chronic exposure leads to downregulation of
LHRH receptors, thereby suppressing LH and
FSH secretion, and ultimately inhibiting
testosterone production. Castration levels of
testosterone with LHRH agonists are typically
achieved within 2–4 weeks [2]. LHRH
antagonists, such as degarelix, are an
alternative form of ADT. They inhibit LHRH
receptors, leading to a rapid decrease in LH,
FSH, and testosterone levels, without the
testosterone flare associated with LHRH
agonists [2].
Clinical trials have compared the effects of
LHRH agonists and LHRH antagonists on
prostate-specific antigen (PSA) and
testosterone levels, but large comparative trials
are needed to provide overall survival and/or
progression-free survival data [3]. Previous
studies have also reported LHRH agonists and
LHRH antagonists to be generally well tolerated
(with most adverse events being consistent with
androgen suppression or the underlying
condition), with the exception of reactions at
the injection site with LHRH antagonists [4–8].
Switching between hormonal therapies has
been reported to have clinical benefits [6, 8–10].
There are currently no clinical guidelines for
switching between LHRH analogues [2, 11, 12],
but it has been reported that there could
potentially be clinical benefits for patients if
they switch between the different formulations
of LHRH agonists [8] as well as from an LHRH
agonist to LHRH antagonist [6, 10]. There have,
however, been no published data reported for
switching from an LHRH antagonist to an
LHRH agonist. Here we summarize the clinical
notes of 10 patients with hormone-sensitive
advanced prostate cancer who switched from an
LHRH antagonist to an LHRH agonist.
CASE PRESENTATION
Ten patients with T3N0M0–T4N1M1 prostate
cancer experiencing injection site reactions,
such as pain and swelling, with monthly
degarelix (Firmagon) subcutaneous injections
were included within this collection of 10 case
studies (Fig. 1). Mean patient age was 75 years
[standard deviation (SD) 8.3; range 59–85] and
Gleason scores ranged from 7 to 9 (Table 1). All
patients provided informed consent and the
study was carried out in accordance with ethical
standards and Good Clinical Practice.
Primary treatment for prostate cancer was
external beam radiation therapy (n = 9) or
chemical castration (n = 1). The mean (± SD)
duration of degarelix treatment was
5 ± 3.7 months (range 2–13). The first patient
was switched to the leuprorelin acetate implant
(Leuprorelin Sandoz), with no antiandrogen
therapy, in December 2015 and the mean
duration of treatment is currently 7 months
(range 4–10). Of the 10 patients who switched
from degarelix, three received the
leuprorelin acetate implant before radiotherapy
as neoadjuvant therapy and the seven men who
received it as adjuvant therapy are still receiving
the implant (Fig. 1). PSA levels were measured
before and after switching treatments [time to
post-switch PSA measurement, 1–6 months,
mean 2.2 ± 1.6 (SD)]. PSA levels were
comparable or reduced from those measured
prior to switching, showing that efficacy was
not compromised (Fig. 2). Mean PSA level
before switching was 6.1 ± 9.1 versus
4.4 ± 6.7 ng/mL after switching.
Throughout the course of treatment, no
patients reported injection site reactions, such
as pain or swelling, with the leuprorelin acetate
implant. Patients reported increased satisfaction
with the leuprorelin acetate implant than with
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degarelix, mainly because of a lack of injection
site reactions and reduced frequency of
injection. Moreover, the 3-month injection
interval with the leuprorelin acetate implant
was reported by the patients to be preferable to
the monthly interval of degarelix. Following the
switch to the leuprorelin acetate implant in the
adjuvant setting, all seven patients stated that
they preferred to continue with this therapy.
In Finland, continuous treatment with the
leuprorelin acetate implant also appeared to be
more cost-effective due to reduced costs
(decreased from €517 for 3 months treatment
with degarelix to €316 for the leuprorelin
acetate implant). In addition, costs associated
with nurse involvement were reduced to
one-third of the original cost due to less
frequent administration of injections.
Fig. 1 Patient ﬂow diagram
Table 1 Baseline characteristics and time to the ﬁrst PSA test after switching to the leuprorelin acetate implant
Patient Gleason score Gleason sum cTNM Time to ﬁrst PSA test
after the switch (months)
1 4 ? 5 9 T3N0M0 2
2 4 ? 3 7 T3N0M0 1
3 5 ? 4 9 T4N1M1 4
4 4 ? 4 8 T3N0M0 2
5 4 ? 5 9 T3N0M0 6
6 4 ? 4 8 T3N0M0 2
7 4 ? 4 8 T3N0M0 2
8 4 ? 5 9 T3N0M0 1
9 4 ? 5 9 T3N1M1 1




This is the first report of the clinical experience
and the potential for associated cost savings
when switching men with advanced prostate
cancer from an LHRH antagonist to an LHRH
agonist. The recurrent injection site reactions
experienced by all 10 Finnish patients who
initially received degarelix could be attributed
to the associated histamine release from mast
cells, which has been associated with all LHRH
antagonists [13]. The data reported here for men
switching from degarelix to the leuprorelin
acetate implant are consistent with other
switching experiences between LHRH analogues
in terms of efficacy and safety [6, 8, 10] as well as
the potential for associated for cost savings [1].
The case report presented here, therefore,
provides preliminary evidence that the switch
from an LHRH antagonist to an agonist is safe
and equally efficacious. However, a prospective
patient preference study reporting local
adverse effects would be useful to support
these findings, as well as a large comparative
trial to compare overall survival and/or
progression-free survival of LHRH agonists and
LHRH antagonists [3].
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Fig. 2 PSA levels of 10 patients measured before and after switching from an LHRH antagonist to an LHRH agonist
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